Synlogic Inc
Company Overview
Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on developing synthetic biology medicines. The company designs and develops Synthetic Biotics, which are engineered beneficial microbes programmed to treat diseases in new ways. Their primary focus is on developing treatments for metabolic and immunological diseases.
The company's lead programs include treatments for Phenylketonuria (PKU) and Homocystinuria (HCU), both rare genetic metabolic disorders. They use synthetic biology to engineer probiotics that can perform specific functions in the body to treat disease.
Use of Interest
Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
March 31, 2024 | $8000.0 | $38.85m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Synlogic Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.